Visugromab

• Target :

  PD-1/PD-L1|||TGF-beta/Smad

• Related Pathways :

  Apoptosis|||Stem Cells|||Cell Cycle/Checkpoint|||Immunology/Inflammation

• Purity :

  0.988

• Bioactivity :

  Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2556646-63-8